Assessing the impact of lipoprotein a levels on survival in pancreatic cancer patients
Lipoprotein a is an Independent Risk Factor for Overall Survival in Patients With Pancreatic Cancer: a Propensity Score Matching Analysis
This study looks at whether the levels of a specific protein in the blood can help predict how long people with pancreatic cancer will live and how well they respond to treatment.
Quick facts
| Study type | Observational |
|---|---|
| Enrollment | 360 (estimated) |
| Ages | 18 Years and up |
| Sex | All |
| Sponsor | The Affiliated Hospital of Qingdao University Academic / other |
| Drugs / interventions | chemotherapy, radiation |
| Locations | 1 site (Qingdao, Shandong) |
| Trial ID | NCT06316466 on ClinicalTrials.gov |
What this trial studies
This observational study evaluates the prognostic significance of serum lipoprotein (a) levels on overall survival and progression-free survival in patients diagnosed with pancreatic cancer. A retrospective analysis was conducted on the clinicopathological data of 364 patients from the Affiliated Hospital of Qingdao University. Using propensity score matching, patients were categorized into high and low lipoprotein (a) groups, and their survival outcomes were compared through Kaplan-Meier methods and Cox-regression analyses to identify prognostic factors.
Who should consider this trial
Good fit: Ideal candidates include adult patients over 18 years with histologically confirmed pancreatic cancer and complete lipid profiles available.
Not a fit: Patients with concurrent malignancies or those who have undergone previous treatments like pancreatectomy, chemotherapy, or radiation therapy may not benefit from this study.
Why it matters
Potential benefit: If successful, this study could provide insights into the role of lipoprotein (a) as a prognostic marker, potentially guiding treatment decisions for pancreatic cancer patients.
How similar studies have performed: While the specific approach of using lipoprotein (a) as a prognostic factor in pancreatic cancer is less common, similar studies have shown promise in identifying biomarkers for cancer prognosis.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Adult patients aged over 18 years; (2) Patients with histologically confirmed pancreatic cancer through surgical or puncture procedures; (3) Complete lipid profiles available within one week prior to diagnosis. Exclusion Criteria: * (1) Presence of concurrent malignancies; (2) History of previous treatments such as pancreatectomy, chemotherapy, or radiation therapy; (3) Incomplete clinicopathological information.
Where this trial is running
Qingdao, Shandong
- Affiliated Hospital of Qingdao University — Qingdao, Shandong, China (Recruiting)
Study contacts
- Study coordinator: Jinyue liu
- Email: liujinyue99@163.com
- Phone: 17854269227
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.